Identification of a lactylation-related gene signature to characterize subtypes of hepatocellular carcinoma using bulk sequencing data

• Published in: Journal of gastrointestinal oncology Vol. 15; no. 4; pp. 1636 - 1646
• Main Authors: Chen, Yan, Chang, Li, Hu, Ling, Yan, Cuiping, Dai, Liu, Shelat, Vishal G, Yarmohammadi, Hooman, Sun, Jun
• Format: Journal Article
• Language: English
• Published: China AME Publishing Company 31-08-2024
• Subjects: Original; lactylation-related gene signature (LRG signature); lactylation; prognostic model; biomarkers; Hepatocellular carcinoma (HCC)
• ISSN: 2078-6891; 2219-679X
• DOI: 10.21037/jgo-24-405

Prior studies indicate that lactylation regulates various biological mechanisms within cancer. However, lactylation-related genes (LRGs) have been found to have limited value in predicting the prognosis of hepatocellular carcinoma (HCC). The aim of this study was to review HCC LRGs using data from The Cancer Genome Atlas (TCGA).
The RNA sequencing data and related clinical information of patients with HCC patients were collected from the TCGA database. A total of 20 LRGs were selected and bioinformatics analysis was performed. A consistency cluster analysis was conducted to classify the HCC tumors. Using a lactylation-related model of HCC, prognosis, immune cell infiltration, and immunotherapy was evaluated.
A total of 4,378 genes were associated with prognosis. Twenty LRGs (i.e.,
, and
) were identified. The 20 LRGs were used to divide TCGA-HCC patients into low-risk (G1) and high-risk (G2) categories. The upregulated genes in the G1 group primarily participate in the p53 signaling pathway, focal adhesion, extracellular matrix (ECM)-receptor interaction, and cell cycle, while the downregulated genes primarily participate in the glycolysis/gluconeogenesis, carbon metabolism, and biosynthesis of amino acids. The box plots showed a significant difference in the immune cell populations, with a higher abundance of B cells, CD4
T cells, CD8
T cells, neutrophils, macrophages, and myeloid dendritic cells in the G1 than the G2 HCC samples. Further, the box plots showed higher expression levels of seven of the eight immune checkpoint inhibitor (ICI)-related genes in the G1 HCC samples than the G2 samples. There was a significant disparity in the cancer stem cell (CSC) scores between the G1 and G2 TCGA-HCC patients. Additionally, the G1 TCGA-HCC patients had higher tumor immune dysfunction and exclusion (TIDE) scores than the G2 TCGA-HCC patients. The prognosis of the HCC patients was also predicted using a six-LRG model, comprising
, and
.
Strong correlation between LRGs and tumor classification as well as immunity in patients with HCC was identified. LRG signatures serve as reliable prognostic markers for HCC.